Practice guidelines for tumor marker use in the clinic

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1151-1159

  Sturgeon, Catharine ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATECHOLAMINE; CHORIONIC GONADOTROPIN; CYTOKERATIN 19 FRAGMENT; ESTROGEN RECEPTOR; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR MARKER; VANILMANDELIC ACID;

BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; EVIDENCE BASED MEDICINE; GERM CELL TUMOR; HUMAN; LUNG CANCER; NEUROENDOCRINE TUMOR; ONCOGENE NEU; OVARY CANCER; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; REVIEW; THYROID CANCER;

EID: 0036328377     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1151     Document Type: Review

References (64)

1. Evidence based medicine: What it is and what it isn't
2. Evidence-based laboratory medicine: Supporting decision-making
3. Potential benefits, limitations, and harms of clinical guidelines
4. Developing guidelines
5. When should clinical guidelines be updated?
6. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
7. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
8. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
9. Practice guidelines and recommendations for use of tumor markers in the clinic
10. Consensus recommendations
11. Standards, options and recommendations (SOR) for tumor markers in breast cancer
12. Standards, options and recommendations: Ovarian cancer
13. Standards, options and recommendations: Hepatocellular carcinoma
14. Standards, options and recommendations: Cancer of the rectum
15. Standards, options and recommendations: Carcinoma of the colon
16. SOR: Project methodology
17. Testicular cancer seen as "stalking horse" for other cancers
18. Consensus statement on the investigation and management of testicular seminoma 1989
19. Tumour markers in germ cell cancers: EGTM recommendations
20. EAU guidelines on testicular cancer
21. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
22. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring
23. ABC of colorectal cancer: The role of primary care
24. American Cancer Society guidelines for early detection of cancer (2002)
25. American Joint Committee on Cancer prognostic factors consensus conference
26. American Joint Committee on Cancer Prognostic Factors consensus conference: Colorectal Working Group
27. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999
28. College of American Pathologists conference XXXV: Solid tumor prognostic factors - Which, how and so what? Summary document and recommendations for implementation
29. Role of follow-up in the management of local recurrence of colorectal cancer: A prospective, randomised study
30. Follow-up of colorectal cancer: A meta-analysis
31. Standards, options and recommendations for tumor markers in colorectal cancer
32. Tumor markers in breast cancer: EGTM recommendations
33. Recent developments in ovarian cancer screening
34. NIH consensus conference. Ovarian cancer: Screening, treatment and follow-up
35. Prostate-specific antigen (PSA) best practice policy
36. Guidelines on the management of prostate cancer. A document for local expert groups in the United Kingdom preparing prostate management policy documents
37. Executive summary of the National Cancer Institute workshop: Highlights and recommendations
38. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy
39. Management of prostate cancer after prostatectomy: Treating the patient not the PSA
40. Tumor markers in lung cancer: EGTM recommendations
41. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2
42. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
43. Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer
44. Quality requirements and control: EGTM recommendations
45. Tumor markers in the laboratory: Closing the guideline-practice gap
46. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of testicular seminoma
47. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT)
48. Tumor markers in gastrointestinal cancers: EGTM recommendations
49. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer
50. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer
51. Tumor markers in gynaecological cancers: EGTM recommendations
52. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer
53. EAU guidelines on prostate cancer
54. Tumour markers in prostate cancer: EGTM recommendations